Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY03010 vs Invega Sustenna PK in Schizophrenia
NCT04572685Phase 1Completed
- Sponsor
- Luye Pharma Group
- Start
- Jan 2020
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of paliperidone in schizophrenia (3 arms), sponsored by Luye Pharma Group. Primary endpoints: Maximum Plasma Concentration at 120 Days, Area under the plasma concentration versus time curve at 120 Days and 2 more. Started Jan 2020; status: completed.
02
Drugs
paliperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT04572685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04572685.